AC Immune SA of Switzerland has extended its cash runway into 2027 following receipt of a milestone payment from partner Janssen Pharmaceutical Inc and contract revenue from other collaborations for its portfolio of medicines and diagnostics for Alzheimer’s and Parkinson’s diseases. Cash on 30 September was CHF 157.9 million ($178.78), up from CHF 103.1 million on 31 December 2023. This was bumped up in October with a CHF 24.6 million payment from Janssen.
